Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome

We propose a likely contribution to severe COVID-19 morbidity by extracellular DNA in neutrophil extracellular traps (NETs). Dornase alfa degrades extracellular DNA to reduce mucus rigidity and accumulation, and was associated with respiratory improvement in a first patient. Dornase alfa should be c...

Descripción completa

Detalles Bibliográficos
Autores principales: Earhart, A.P., Holliday, Z.M., Hofmann, H.V., Schrum, A.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192073/
https://www.ncbi.nlm.nih.gov/pubmed/32355564
http://dx.doi.org/10.1016/j.nmni.2020.100689
Descripción
Sumario:We propose a likely contribution to severe COVID-19 morbidity by extracellular DNA in neutrophil extracellular traps (NETs). Dornase alfa degrades extracellular DNA to reduce mucus rigidity and accumulation, and was associated with respiratory improvement in a first patient. Dornase alfa should be considered for clinical trials in treatment of severe COVID-19.

Ejemplares similares